April 25, 2025
The US Food and Drug Administration (FDA) has approved penpulimab-kcqx (Akeso Biopharma) in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adults with […]
April 25, 2025
The National Institute for Health and Care Excellence (NICE) has recommended ribociclib (Kisqali, Novartis) as an adjuvant treatment for early breast cancer in patients at high […]
April 25, 2025
The October 2024 approval of inavolisib for advanced breast cancer spotlighted a growing problem in breast oncology: Managing the hyperglycemia caused by phosphoinositide 3-kinase (PI3K)/Akt pathway […]
April 25, 2025
Overall cancer deaths in the United States continue to decline, but trends are mixed when it comes to deaths associated with specific cancer types and overall […]
April 24, 2025
TOPLINE: Heterogeneous escalation of radiotherapy dose guided by imaging in locally advanced non–small cell lung cancer (NSCLC) does not increase early toxicity, a new trial found. […]
April 23, 2025
Although targeted therapies and immunotherapy have improved survival outcomes in many patients with lung cancer, these therapies come at a cost, not only financially but also […]
April 23, 2025
The National Institute for Health and Care Excellence (NICE) has recommended nivolumab (Opdivo) plus ipilimumab (Yervoy) for some people in England with advanced colorectal cancer. The […]
April 23, 2025
TOPLINE: Women diagnosed with metabolic syndrome at the time of their breast cancer diagnosis had a significantly higher risk for recurrence and mortality than those without […]
April 22, 2025
Neoantigen-specific tumor-infiltrating lymphocytes (TILs) plus pembrolizumab demonstrate efficacy against treatment-refractory gastrointestinal (GI) cancers in early results from a phase 2 trial. This is the first clinical […]